Switching from adalimumab originator to biosimilar: a 3-year retrospective cohort analysis

被引：0
|
作者：
Killion, Lisa [1 ]
Alsharqi, Ali [1 ]
Kirby, Brian [1 ]
机构：
[1] St Vincents Hosp, Dublin, Ireland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
D O I：
10.1093/bjd/ljad113.113
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P85
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest
    Kirsten, Natalia
    Ohm, Frenz
    Gehrdau, Kathrin
    Girbig, Gefion
    Stephan, Brigitte
    Ben-Anaya, Nesrine
    Pinter, Andreas
    Bechara, Falk G.
    Presser, Dagmar
    Zouboulis, Christos C.
    Augustin, Matthias
    LIFE-BASEL, 2022, 12 (10):
  • [32] Comparison of discontinuation/switching between adalimumab biosimilar and originator in Inflammatory Bowel Disease patients: Preliminary data from CAN-AIM
    Lukusa, L.
    Birck, M. G.
    Moura, C. S.
    Neville, A.
    Zezos, P.
    Narula, N.
    Targownik, L. E.
    Ma, C.
    Purdy, E.
    Afif, W.
    Singh, H.
    Oketola, B.
    Bernatsky, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I2069 - I2070
  • [33] EFFECTIVENESS AND SAFETY OF ABP501, AN ADALIMUMAB BIOSIMILAR, IN NAIVE PATIENTS WITH IBD AND IN THOSE UNDERGOING SWITCHING FROM ADALIMUMAB ORIGINATOR: A MULTICENTRIC NORTH ITALIAN STUDY.
    Barberio, Brigida
    Zingone, Fabiana
    Melatti, Piera
    Ferronato, Antonio
    Buda, Andrea
    Bertani, Lorenzo
    Bodini, Giorgia
    Gubbiotti, Alessandro
    Massimi, Davide
    Lorenzon, Greta
    Savarino, Edoardo
    GASTROENTEROLOGY, 2020, 158 (06) : S410 - S410
  • [34] Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study
    Papoutsaki, M.
    Chimenti, M. S.
    Talamonti, M.
    Zangrilli, A.
    Teoli, M.
    Kroegler, B.
    Perricone, R.
    Chimenti, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (06) : 1414 - 1414
  • [35] Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto
    Catherine Pham
    Fang Niu
    Rita L. Hui
    Kim N. Le
    Thomas Delate
    Clinical Rheumatology, 2024, 43 : 1269 - 1270
  • [36] Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-atto
    Pham, Catherine
    Niu, Fang
    Hui, Rita L.
    Le, Kim N.
    Delate, Thomas
    CLINICAL RHEUMATOLOGY, 2024, 43 (03) : 1269 - 1270
  • [37] Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis
    Deaner, Jordan D.
    Srivastava, Sunil K.
    Hajj-Ali, Rula A.
    Lowder, Careen Y.
    Venkat, Arthi G.
    Baynes, Kimberly
    Sharma, Sumit
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2021, 225 : 172 - 177
  • [38] NON-MEDICAL SWITCHING FROM ORIGINATOR TO BIOSIMILAR ETANERCEPT - NO EVIDENCE FOR A RELEVANT NOCEBO EFFECT - A RETROSPECTIVE ANALYSIS OF REAL-LIFE DATA
    Kiltz, Uta
    Tsiami, Styliani
    Baraliakos, Xenofon
    Braun, Juergen
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 716 - 717
  • [39] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
  • [40] OUTCOMES FOLLOWING SWITCHING FROM ORIGINATOR TO BIOSIMILAR IN CHILDREN AND YOUNG PEOPLE WITH JIA
    Kearsley-Fleet, L.
    Baildam, E.
    Beresford, M.
    Douglas, S.
    Foster, H.
    Southwood, T.
    Hyrich, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 285 - 285
12345